You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

acalabrutinib

Showing 1 - 25 of 137
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Lymphocytic Leukemia Trial (Acalabrutinib, Obinutuzumab)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • (no location specified)
Jul 10, 2023

DLBCL Trial (Acalabrutinib, Rituximab)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Acalabrutinib
  • Rituximab
  • (no location specified)
Jul 11, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (Nemtabrutinib, Ibrutinib, Acalabrutinib)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • (no location specified)
Nov 22, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial run by the (Acalabrutinib (Arm A), Acalabrutinib (Arm B))

Active, not recruiting
Has Results
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Acalabrutinib (Arm A)
  • Acalabrutinib (Arm B)
  • Bethesda, Maryland
    Research Site
Jan 3, 2023

Post-transplant Lymphoproliferative Disorder Trial in Cleveland (Rituximab, Acalabrutinib, CT scans)

Active, not recruiting
  • Post-transplant Lymphoproliferative Disorder
  • Cleveland, Ohio
    Cleveland Clinic, Case Comprehensive Cancer Center
Jan 16, 2023

Mantle Cell Lymphoma Trial (Acalabrutinib, Rituximab)

Not yet recruiting
  • Mantle Cell Lymphoma
  • (no location specified)
Oct 31, 2022

Retention Rate of Acalabrutinib in a Non-interventional Setting

Recruiting
  • Chronic Lymphocytic Leukaemia (CLL)
    • Zittau, Germany
      Research Site
    Jan 12, 2023

    Acalabrutinib in Chronic Lymphocytic Leukaemia in United Kingdom

    Recruiting
    • Chronic Lymphocytic Leukemia, CLL
    • Acalabrutinib
    • Aylesbury, United Kingdom
    • +7 more
    Jan 12, 2023

    Bioequivalence Trial in Glendale, Brooklyn, Salt Lake City (Treatment A: Acalabrutinib tablet, Treatment B: Acalabrutinib

    Completed
    • Bioequivalence
    • Treatment A: Acalabrutinib tablet
    • Treatment B: Acalabrutinib capsule
    • Glendale, California
    • +2 more
    Jul 7, 2022

    Mantle Cell Lymphoma (MCL) Trial in Australia, Canada, United States (Acalabrutinib, Venetoclax, Rituximab)

    Not yet recruiting
    • Mantle Cell Lymphoma (MCL)
    • Acalabrutinib
    • +2 more
    • Duarte, California
    • +11 more
    Jul 17, 2023

    T-cell Lymphoma, CLL/SLL Trial in Birmingham (Tazemetostat, Acalabrutinib and Tazemetostat)

    Not yet recruiting
    • T-cell Lymphoma
    • CLL/SLL
    • Birmingham, Alabama
      University of Alabama at Birmingham
    Aug 11, 2023

    Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Homburg (R-miniCHOP + Acalabrutinib, R-miniCHOP)

    Not yet recruiting
    • Large B-cell Lymphoma
    • Diffuse Large B Cell Lymphoma
    • Homburg, Saarland, Germany
      Saarland University Medical Center
    Apr 19, 2023

    Mantle Cell Lymphoma Trial in Houston (Acalabrutinib)

    Recruiting
    • Mantle Cell Lymphoma
    • Acalabrutinib
    • Houston, Texas
      M D Anderson Cancer Center
    Aug 22, 2022

    Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

    Not yet recruiting
    • Recurrent Chronic Lymphocytic Leukemia
    • +3 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jan 10, 2023

    Chronic Lymphocytic Leukemia Trial in Houston (Ibrutinib, Venetoclax)

    Recruiting
    • Chronic Lymphocytic Leukemia
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 21, 2022

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Scottsdale, Jacksonville, Rochester (drug, other, biological)

    Recruiting
    • Chronic Lymphocytic Leukemia
    • Small Lymphocytic Lymphoma
    • Acalabrutinib
    • +4 more
    • Scottsdale, Arizona
    • +2 more
    Jan 5, 2023

    Chronic Lymphocytic Leukemia (CLL) Trial in United States (Venetoclax, Obinutuzumab, Acalabrutinib)

    Active, not recruiting
    • Chronic Lymphocytic Leukemia (CLL)
    • Stamford, Connecticut
    • +4 more
    Dec 2, 2022

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (Acalabrutinib, Obinutuzumab, Venetoclax)

    Recruiting
    • Chronic Lymphocytic Leukemia
    • Small Lymphocytic Lymphoma
    • Acalabrutinib
    • +2 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Nov 2, 2022

    Blastoid Variant Mantle Cell Lymphoma, CCND1 Protein Overexpression, CD20 Positive Trial in Houston (Acalabrutinib, Venetoclax)

    Recruiting
    • Blastoid Variant Mantle Cell Lymphoma
    • +8 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 5, 2022

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia Trial in Boston (Acalabrutinib,

    Active, not recruiting
    • Chronic Lymphocytic Leukemia
    • +3 more
    • Acalabrutinib
    • +2 more
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Dec 19, 2022

    IgM MGUS, Waldenstrom Macroglobulinemia, Neuropathy;Peripheral Trial in Boston (Acalabrutinib, Rituximab)

    Recruiting
    • IgM MGUS
    • +2 more
    • Boston, Massachusetts
    • +1 more
    Nov 14, 2022

    National Acalabrutinib Observational Study

    Not yet recruiting
    • Chronic Lymphocytic Leukemia
    • Non interventional study
    • (no location specified)
    Jun 27, 2022

    Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma Trial in Rochester (Acalabrutinib, Durvalumab,

    Recruiting
    • Chronic Lymphocytic Leukemia
    • +2 more
    • Acalabrutinib
    • +2 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    Jan 4, 2023

    Chronic Lymphocytic Leukemia (CLL) Trial in Boston (Ibrutinib, Copanlisib, Acalabrutinib)

    Recruiting
    • Chronic Lymphocytic Leukemia (CLL)
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    May 13, 2022

    Non Hodgkin Lymphoma Trial in United Kingdom (R-CHOP + acalabrutinib)

    Active, not recruiting
    • Non Hodgkin Lymphoma
    • R-CHOP + acalabrutinib
    • Southampton, Hampshire, United Kingdom
    • +6 more
    Oct 26, 2022